Diaceutics PLC (DIUXF)
- Previous Close
1.3380 - Open
1.3672 - Bid --
- Ask --
- Day's Range
1.3672 - 1.3672 - 52 Week Range
1.3672 - 1.3672 - Volume
47,746 - Avg. Volume
0 - Market Cap (intraday)
115.558M - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialisation platform for precision medicine that integrates multiple pipelines of diagnostic testing data from network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and the physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers professional services, such as market landscape, implementation, and consulting services. It operates in North America, the United Kingdom, Europe, Asia, and internationally. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
www.diaceutics.com199
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DIUXF
View MorePerformance Overview: DIUXF
Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DIUXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DIUXF
View MoreValuation Measures
Market Cap
156.86M
Enterprise Value
141.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.30%
Return on Assets (ttm)
-3.23%
Return on Equity (ttm)
-4.22%
Revenue (ttm)
32.16M
Net Income Avi to Common (ttm)
-1.7M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
12.74M
Total Debt/Equity (mrq)
2.66%
Levered Free Cash Flow (ttm)
-2.35M